Alzheimer's disease drug-development pipeline: few candidates, frequent failures (Q33892815)

29 July 2017

Alzheimer's disease drug-development pipeline: few candidates, frequent failures (English)

1 reference

29 July 2017

0 references

1

Jeffrey L Cummings

1 reference

29 July 2017

Travis Morstorf

2

1 reference

29 July 2017

Kate Zhong

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

3 July 2014

1 reference

Alzheimers Research & Therapy

29 July 2017

1 reference

29 July 2017

6

1 reference

29 July 2017

37

1 reference

29 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1186/alzrt269

29 July 2017

0 references

cites work

Clinical development success rates for investigational drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Monetary costs of dementia in the United States

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Was phenserine a failure or were investigators mislead by methods?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Alzheimer's disease and the amyloid cascade hypothesis: a critical review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Evaluation of drugs with specific organ toxicities in organ-specific cell lines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Globalization of Alzheimer's disease clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Report of the task force on designing clinical trials in early (predementia) AD.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Modeling an anti-amyloid combination therapy for Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

How to improve R&D productivity: the pharmaceutical industry's grand challenge

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Of mice and men: bridging the translational disconnect in CNS drug discovery

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Increasing the success rate for Alzheimer's disease drug discovery and development.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

Mapping the road forward in Alzheimer's disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4095696

2013 Alzheimer's disease facts and figures

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25024750

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/ALZRT269

1 reference

Dimensions Publication ID

29 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/alzrt269

9 September 2019

1 reference

29 July 2017

1 reference